Following the review of the Oxford-AstraZeneca Covid-19 vaccine by the European Medicines Agency (EMA), which concluded it as "safe and effective," RPS Chief Scientist Professor Gino Martini said:
“I hope that any concerns about potential links between the Oxford-AstraZeneca Covid-19 vaccine and blood clots can now be discarded given the positive verdicts delivered by the EMA, the WHO and the MHRA, who have all now said the vaccine is safe, effective and can continue to be used. The vaccine is playing a crucial role in protecting vulnerable groups from hospitalisation and death and helping to decrease infection rates across the UK.
“The MHRA is renowned as a world-class regulator of medicines and vaccines. They are continuing to monitor the Oxford/AstraZeneca vaccine closely as part of a ‘rolling review’ approach to COVID-19 jabs, through rigorous checks and processes, at they would for any other vaccine or medicine. Regulators are continuing to monitor and investigate some very rare instances of a blood clot in the brain.
“As trusted health professionals, pharmacists are playing a key role in administering COVID-19 vaccinations and have contributed enormously to the success of the programme so far. We have full confidence in these vaccines and can confidently state that pharmacists can continue administering them to patients. It is so important that we get all those at risk from the virus vaccinated as soon as possible.”